Cancer treatment, primarily chemotherapy, is associated with impaired cardiorespiratory fitness years after treatment has ...

With Black mental health gaining national attention, The Black Therapy Network (BTN) is launching to ensure culturally competent therapy is accessible to all. Black Americans are 50% less likely to ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...

Innate Pharma has gained breakthrough therapy designation for lacutamab to treat adults with relapsed or refractory Sézary ...

Innate Pharma shares were up 16% to $2.25 after the company said the Food and Drug Administration has granted Breakthrough Therapy Designation to lacutamab for the treatment of adult patients with ...

In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.

Lasers are the most common light sources utilized in acne therapy, which produce a high-energy beam of light of a precise wavelength range. A range of treatments are being investigated ...

GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Michael Staehler discussing 18 F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell ...

In England, the maturing of the Systemic Anti-Cancer Therapy (SACT) dataset could help provide some answers. The commitment to SACT began in 2011, followed by phased implementation across the ...